[go: up one dir, main page]

DE69910604D1 - Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit" - Google Patents

Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit"

Info

Publication number
DE69910604D1
DE69910604D1 DE69910604T DE69910604T DE69910604D1 DE 69910604 D1 DE69910604 D1 DE 69910604D1 DE 69910604 T DE69910604 T DE 69910604T DE 69910604 T DE69910604 T DE 69910604T DE 69910604 D1 DE69910604 D1 DE 69910604D1
Authority
DE
Germany
Prior art keywords
formulation
production
type
controlled release
multiple unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69910604T
Other languages
English (en)
Other versions
DE69910604T2 (de
Inventor
Torkel Gren
Anders Ringberg
Martin Wikberg
J Wald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69910604(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of DE69910604D1 publication Critical patent/DE69910604D1/de
Publication of DE69910604T2 publication Critical patent/DE69910604T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69910604T 1998-11-11 1999-11-11 Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit" Expired - Lifetime DE69910604T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9803871 1998-11-11
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
WOPCT/SE99/01463 1999-08-26
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Publications (2)

Publication Number Publication Date
DE69910604D1 true DE69910604D1 (de) 2003-09-25
DE69910604T2 DE69910604T2 (de) 2004-06-24

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69910604T Expired - Lifetime DE69910604T2 (de) 1998-11-11 1999-11-11 Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit"

Country Status (40)

Country Link
US (1) US6911217B1 (de)
EP (1) EP1128819B1 (de)
JP (1) JP3616011B2 (de)
KR (1) KR100467384B1 (de)
CN (1) CN1169522C (de)
AP (1) AP1323A (de)
AR (1) AR027815A1 (de)
AT (1) ATE247458T1 (de)
AU (1) AU762410B2 (de)
BG (1) BG65149B1 (de)
BR (1) BRPI9915142B8 (de)
CA (1) CA2350061C (de)
CZ (1) CZ299582B6 (de)
DE (1) DE69910604T2 (de)
DK (1) DK1128819T3 (de)
EA (1) EA005074B1 (de)
EE (1) EE05232B1 (de)
ES (1) ES2204193T3 (de)
GE (1) GEP20022833B (de)
HK (1) HK1040917B (de)
HR (1) HRP20010333B1 (de)
HU (1) HU226582B1 (de)
ID (1) ID30039A (de)
IL (1) IL142809A0 (de)
IS (1) IS2370B (de)
MA (1) MA25325A1 (de)
MY (1) MY122195A (de)
NO (1) NO331399B1 (de)
NZ (1) NZ511430A (de)
OA (1) OA11673A (de)
PL (1) PL195780B1 (de)
PT (1) PT1128819E (de)
RS (1) RS49891B (de)
SE (1) SE9803871D0 (de)
SI (1) SI1128819T1 (de)
SK (1) SK284758B6 (de)
TW (2) TWI267385B (de)
UA (1) UA57165C2 (de)
WO (1) WO2000027364A1 (de)
ZA (1) ZA200103575B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (de) 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
CZ304671B6 (cs) * 1999-11-11 2014-08-27 Pharmacia Ab Farmaceutický prostředek obsahující tolterodin a jeho použití
US7101888B2 (en) * 2002-08-28 2006-09-05 Pharmacia & Upjohn Company Oral liquid tolterodine composition
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
DE602004021233D1 (de) * 2003-01-22 2009-07-09 Pfizer Health Ab Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CA2536401C (en) 2003-11-04 2011-08-30 Shire Laboratories Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
PT2210605T (pt) 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (de) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
CA2590555A1 (en) * 2005-01-10 2006-07-13 Teva Pharmaceutical Industries Ltd. Substantially pure tolterodine tartrate and process for preparing thereof
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
EP1885383B1 (de) 2005-05-31 2016-09-21 IAMS Europe B.V. Katzen probiotisches bifidobacterium
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP3510988B1 (de) 2006-01-18 2021-07-14 Intec Pharma Ltd. Verabreichungsvorrichtung zur oralen einnahme eines mittels
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
WO2007097770A1 (en) * 2006-02-24 2007-08-30 Teva Pharmaceutical Industries Ltd. Metoprolol succinate e.r. tablets and methods for their preparation
CA2645940A1 (en) * 2006-03-21 2007-09-27 Teva Pharmaceutical Industries Ltd. Controlled release formulation of tolterodine
EP1839649A1 (de) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Beschichtete Formulierung von Tolterodine
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (de) 2006-05-17 2009-02-25 Synthon B.V. Tabletten-zusammensetzung mit verlängerter freisetzung von tamsulosin
PT3357496T (pt) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
BRPI0719280A2 (pt) 2006-11-27 2014-03-11 Lundbeck & Co As H Composto, composição farmacêutica, métodos para modular a atividade de um receptor de p2x7 in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, para determinar a presença ou ausência de receptor de p2x7 em uma amostra, preparação farmacêutica acondicionada, método para tratar ou prevenir cirrose em um paciente, e, uso de um composto.
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
JP5444212B2 (ja) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
EP2762132A1 (de) 2007-04-25 2014-08-06 Cytochroma Inc. Orale Zusammensetzungen mit kontrollierter Freisetzung mit einer Vitamin-D-Verbindung und einem wachsartigen Träger
EP3335712B1 (de) 2007-04-25 2025-09-10 Opko Renal, LLC Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus bei chronischer nierenerkrankung
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (de) * 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Tolterodinhaltige zusammensetzungen mit verzögerter freisetzung
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
KR101852042B1 (ko) 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
WO2009140557A2 (en) * 2008-05-14 2009-11-19 Capricorn Pharma, Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
EP2459180A1 (de) * 2009-07-31 2012-06-06 Ranbaxy Laboratories Limited Mehrschichtige pharmazeutische zusammensetzungen mit mehreren einheiten
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
BR112012024432A2 (pt) 2010-03-29 2016-05-31 Ferring Bv composição farmacêutica de dissolução rápida
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
US9999590B2 (en) 2012-07-12 2018-06-19 Ferring B.V. Diclofenac formulations
JP2015529255A (ja) * 2012-09-20 2015-10-05 オーエイチアール ファーマ， エルエルシーＯｈｒ Ｐｈａｒｍａ， Ｌｌｃ 治療薬の持続放出のための多層の生体分解可能なマイクロ粒子
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
HUE050303T2 (hu) * 2013-03-13 2020-11-30 Intervet Int Bv Stabil bioaktív szubsztanciák és eljárások elõállítására
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA3018328A1 (en) * 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
JP6924177B2 (ja) * 2016-02-23 2021-08-25 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤
KR20230056790A (ko) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
AP1323A (en) 2004-11-05
EA200100538A1 (ru) 2001-10-22
EA005074B1 (ru) 2004-10-28
CN1326339A (zh) 2001-12-12
EE200100254A (et) 2002-12-16
DE69910604T2 (de) 2004-06-24
UA57165C2 (uk) 2003-06-16
BG65149B1 (bg) 2007-04-30
PL348612A1 (en) 2002-06-03
NZ511430A (en) 2003-05-30
CZ20011627A3 (cs) 2001-10-17
KR100467384B1 (ko) 2005-01-24
DK1128819T3 (da) 2003-12-01
HRP20010333A2 (en) 2003-04-30
JP2003517446A (ja) 2003-05-27
SK6252001A3 (en) 2002-01-07
AU762410B2 (en) 2003-06-26
EE05232B1 (et) 2009-12-15
HRP20010333B1 (en) 2004-10-31
CA2350061A1 (en) 2000-05-18
CN1169522C (zh) 2004-10-06
CZ299582B6 (cs) 2008-09-10
SI1128819T1 (en) 2003-12-31
ATE247458T1 (de) 2003-09-15
ID30039A (id) 2001-11-01
WO2000027364A1 (en) 2000-05-18
BRPI9915142B8 (pt) 2021-05-25
IS5936A (is) 2001-05-09
TWI222879B (en) 2004-11-01
SE9803871D0 (sv) 1998-11-11
NO20012314L (no) 2001-07-09
HK1040917B (zh) 2005-05-27
AP2001002166A0 (en) 2001-06-30
TWI267385B (en) 2006-12-01
AU1436600A (en) 2000-05-29
PL195780B1 (pl) 2007-10-31
EP1128819B1 (de) 2003-08-20
JP3616011B2 (ja) 2005-02-02
AR027815A1 (es) 2003-04-16
OA11673A (en) 2005-01-12
PT1128819E (pt) 2003-12-31
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
IL142809A0 (en) 2002-03-10
SK284758B6 (sk) 2005-11-03
US6911217B1 (en) 2005-06-28
CA2350061C (en) 2005-05-17
HUP0105038A2 (en) 2002-06-29
EP1128819A1 (de) 2001-09-05
YU33101A (sh) 2003-10-31
HUP0105038A3 (en) 2006-07-28
IS2370B (is) 2008-06-15
KR20010075695A (ko) 2001-08-09
BG105582A (en) 2001-12-29
NO331399B1 (no) 2011-12-19
MA25325A1 (fr) 2001-12-31
ES2204193T3 (es) 2004-04-16
BRPI9915142B1 (pt) 2015-08-25
BR9915142A (pt) 2001-08-07
MY122195A (en) 2006-03-31
HU226582B1 (en) 2009-04-28
HK1040917A1 (en) 2002-06-28
GEP20022833B (en) 2002-11-25
NO20012314D0 (no) 2001-05-10

Similar Documents

Publication Publication Date Title
DE69910604D1 (de) Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit"
ATE307576T1 (de) Fenofibrathaltige arzneizusammensetzung mit erhöhter bioverfügbarkeit und verfahren zu deren herstellung
ATE389388T1 (de) Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung
ATA902196A (de) Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
DE69611599D1 (de) Halbaromatische polyamidzusamensetzung und verfahren zu ihrer herstellung
ATE208628T1 (de) Neue antithrombotische formulierung, verfahren zur herstellung und gebrauch davon
DE69529065D1 (de) Härtbare zusammensetzung und verfahren zu ihrer herstellung
DE60036933D1 (de) Härtbare harzzusammensetzung, verfahren zu deren herstellung und mit dieser beschichteter gegenstand
DE69632324D1 (de) Pna-dna-chimäre und pna-synthone zu deren herstellung
DE69710484D1 (de) Übergezogene süsswaren und verfahren zu deren herstellung
DE69410470D1 (de) Modifiziertes konjugiertes diencopolymer, verfahren zu dessen herstellung und zusammensetzung daraus
DE69635345D1 (de) Kautschukzusammensetzung und verfahren zu deren herstellung
HUP0401081A3 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
DE69835139D1 (de) Fäulnisverhindernde emulsionsbeschichtungszusammensetzung, verfahren zur herstellung und mit dieser fäulnisverhindernden zusammensetzung beschichteter gegenstand
AT400295B (de) Orale feste pharmazeutische dosierungsform mit programmierter wirkstofffreisetzung und verfahren zu ihrer herstellung
DE3677478D1 (de) N-benzoylharnstoffverbindungen, diese enthaltende antitumorzusammensetzungen und verfahren zu deren herstellung.
DE69700350D1 (de) 4,5-Diiminopyrazoline, Verfahren zu ihrer Herstellung und diese enthaltende Färbemittel
ATE242762T1 (de) Acrylonitril-derivate, verfahren zu ihrer herstellung und diese enthaltende schädlingsbekämpfungsmittel
DE69313010D1 (de) Dispergierbare Polydextrose, diese enthaltende Zusammensetzungen und Verfahren zu ihrer Herstellung
DE69608679D1 (de) IR-Strahlungsempfindliches Bildaufzeichnungselement und Verfahren zur Herstellung von lithographischen Druckplatten mit diesem Element
ATE219069T1 (de) Neue arylglycinamidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69400136D1 (de) Polyamide mit verbessertem farbverhalten und verbesserter verarbeitbarkeit und verfahren zu ihrer herstellung
ATE177732T1 (de) Benzylsulfid-derivate, verfahren zu deren herstellung und diese enthaltende schädlingsbekämpfungsmittel
ATE234103T1 (de) Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
DE4493996T1 (de) Neue Sulfonate, Verfahren zu deren Herstellung und Bleichmittelzusammensetzung, die diese umfaßt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition